Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug ...

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

Several genetic studies have attempted to explore the fungal factors involved in antiviral responses, but the exact genes and ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...